CASADEI GARDINI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.648
AS - Asia 5.345
EU - Europa 4.850
SA - Sud America 844
Continente sconosciuto - Info sul continente non disponibili 338
AF - Africa 136
OC - Oceania 37
Totale 28.198
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.231
GB - Regno Unito 1.789
SG - Singapore 1.589
CN - Cina 1.028
IT - Italia 841
VN - Vietnam 687
HK - Hong Kong 648
BR - Brasile 645
BD - Bangladesh 445
SE - Svezia 439
FI - Finlandia 402
DE - Germania 390
FR - Francia 242
RU - Federazione Russa 216
TR - Turchia 187
CA - Canada 186
ID - Indonesia 168
IN - India 123
BG - Bulgaria 108
KR - Corea 85
IE - Irlanda 82
JP - Giappone 60
AR - Argentina 58
IQ - Iraq 48
NL - Olanda 48
MX - Messico 37
AE - Emirati Arabi Uniti 34
BE - Belgio 34
UA - Ucraina 34
ZA - Sudafrica 34
PK - Pakistan 33
AT - Austria 31
CH - Svizzera 26
CL - Cile 26
CO - Colombia 26
EC - Ecuador 26
TH - Thailandia 26
CR - Costa Rica 25
JM - Giamaica 25
VE - Venezuela 25
PH - Filippine 23
SA - Arabia Saudita 23
ES - Italia 22
JO - Giordania 22
TT - Trinidad e Tobago 21
EG - Egitto 20
RO - Romania 20
NZ - Nuova Zelanda 19
PL - Polonia 18
AU - Australia 17
GP - Guadalupe 17
GT - Guatemala 17
MY - Malesia 16
PR - Porto Rico 16
HN - Honduras 15
MA - Marocco 15
PE - Perù 15
SV - El Salvador 15
LT - Lituania 14
NI - Nicaragua 14
PT - Portogallo 14
CW - ???statistics.table.value.countryCode.CW??? 13
CZ - Repubblica Ceca 12
KE - Kenya 12
PY - Paraguay 11
UZ - Uzbekistan 11
NP - Nepal 10
BZ - Belize 9
DK - Danimarca 9
DZ - Algeria 9
IL - Israele 9
NO - Norvegia 9
TN - Tunisia 9
IR - Iran 8
AZ - Azerbaigian 7
EE - Estonia 7
SK - Slovacchia (Repubblica Slovacca) 7
TW - Taiwan 7
BO - Bolivia 6
DO - Repubblica Dominicana 6
KZ - Kazakistan 6
OM - Oman 6
PS - Palestinian Territory 6
BY - Bielorussia 5
SC - Seychelles 5
SN - Senegal 5
UY - Uruguay 5
BH - Bahrain 4
ET - Etiopia 4
GA - Gabon 4
HU - Ungheria 4
LU - Lussemburgo 4
RS - Serbia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
BB - Barbados 3
CI - Costa d'Avorio 3
GR - Grecia 3
KG - Kirghizistan 3
KH - Cambogia 3
Totale 27.814
Salva come PNG Salva come JPEG
Città #
Fairfield 2.212
Ashburn 1.826
Santa Clara 1.393
Southend 1.304
Singapore 1.071
Woodbridge 907
Seattle 888
Houston 792
Cambridge 732
Chandler 692
Wilmington 684
Hong Kong 632
San Jose 562
Council Bluffs 546
Helsinki 379
Dearborn 324
Nyköping 307
London 304
Ann Arbor 300
Beijing 205
New York 183
Los Angeles 168
Ho Chi Minh City 164
San Diego 163
Izmir 157
Dong Ket 155
Hanoi 149
Jakarta 147
The Dalles 145
Boardman 129
Lauterbourg 110
Princeton 110
Sofia 106
Phoenix 105
Chicago 103
Milan 102
Sunnyvale 94
Eugene 93
Hefei 80
Dublin 78
Shanghai 75
São Paulo 69
Buffalo 65
Modena 64
Dallas 62
Munich 55
Orem 54
Bremen 47
Seoul 47
Tokyo 47
North Bergen 46
Rome 41
Atlanta 39
Redondo Beach 36
Frankfurt am Main 33
Montreal 31
Redwood City 28
Toronto 28
Bupyeong-gu 27
Naples 27
Columbus 25
Da Nang 24
Mumbai 23
Saint Augustine 23
Brussels 22
Salt Lake City 22
Amman 21
Bologna 21
Nuremberg 21
Amsterdam 20
Chennai 20
Norwalk 20
Rio de Janeiro 20
Springfield 20
Auckland 19
Guangzhou 19
Johannesburg 18
San Francisco 18
San Mateo 18
Baghdad 17
Denver 17
Haiphong 17
Kingston 17
Moscow 17
Paris 17
Zhengzhou 17
Belo Horizonte 16
Jacksonville 16
Kunming 16
Quito 16
San José 16
Turku 16
Brasília 15
Brooklyn 15
Genoa 15
Miano 15
Vienna 15
Charlotte 14
Falkenstein 14
Managua 14
Totale 20.248
Salva come PNG Salva come JPEG
Nome #
Chemotherapy and palliative care near end-of life: Examining the appropriateness at a cancer institute for colorectal cancer patients 631
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: Indicators of suspected adverse reactions 513
Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial 490
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients 402
Metabolic disorders across hepatocellular carcinoma in Italy 398
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 375
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 359
Immunotherapy for colorectal cancer: where are we heading? 347
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 344
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 335
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 333
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 331
Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life 330
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial 327
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 327
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours 326
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 320
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 315
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 310
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 306
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy 305
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 303
1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages 303
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 294
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: Results from the ITACa randomized clinical trial 293
Immunotherapeutic approaches for hepatocellular carcinoma 292
The Italian Rare Pancreatic Exocrine Cancer Initiative 291
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 289
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 289
Prolonged pemetrexed infusion plus gemcitabine in refractory metastatic colorectal cancer: Preclinical rationale and phase II study results 289
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 286
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report and results from a cytoflourimetric assay of platelet fibrinogen receptor 285
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study 284
Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report 279
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation 276
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 274
Right- vs. left-sided metastatic colorectal cancer: Differences in tumor biology and bevacizumab efficacy 271
Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer 271
Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study 270
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 270
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC) 270
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities 270
Complete Response in Patient with Metastatic Breast Cancer Treated with Metronomic Chemotherapy 269
Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial 268
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC) 267
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 265
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 263
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 263
Increase of reports of suspected adverse drug reactions in oncology 261
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 261
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 260
BRAF-mutated colorectal cancer: Clinical and molecular insights 260
Chemoradiotherapy (Gemox plus helical tomotherapy) for unresectable locally advanced pancreatic cancer: A phase II study 257
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 257
EGFR, HER-2 and KRAS in canine gastric epithelial tumors: A potential human model? 255
Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study 254
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 254
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 253
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 251
Improved stool DNA integrity method for early colorectal cancer diagnosis 249
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 249
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 245
Shifts of Faecal Microbiota during Sporadic Colorectal Carcinogenesis 242
Sarcopenia in gastric cancer: when the loss costs too much 242
Radiofrequency Ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival 241
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease 241
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study 240
Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals 240
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: Case report 239
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials 239
Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report 237
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 230
Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab 227
Hemangioblastoma of the gastrointestinal tract: A first case 226
Clustered protocadherins methylation alterations in cancer 225
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials 225
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: Results from a retrospective analysis of the HCC-AVR group 222
Erratum to “Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life” [Eur J Cancer (2016) 69 (110–118)] (S095980491632487X)(10.1016/j.ejca.2016.10.004) 220
Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes 219
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 212
Treatment of squamous cell carcinoma of the anal canal (SCCA): A new era? 208
Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib 207
Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; Potential marker of disease recurrence 203
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019 202
NEMESI: A retrospective observational longitudinal study to investigate italian early breast cancer (EBC) patient characteristics and treatment 202
Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: Results from the ITACa trial 201
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 201
Retrospective Analysis on the Management of Metastatic Gastric Cancer Patients. A Mono-institutional Experience. What happens in Clinical Practice? 199
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: The Bagnacavallo Study 194
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics 194
IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab 188
Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy 187
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 181
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 178
mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus 177
The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis 172
Incorporating alpha-fetoprotein within dimensional criteria for hepatocellular carcinoma transplantation 172
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort 172
BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives 171
Oxidative Molecular Mechanisms Underlying Liver Diseases: From Systems Biology to the Personalized Medicine 171
Totale 26.781
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.778
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.778
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.525 0 0 0 0 68 185 81 122 224 259 376 210
2022/20232.022 227 196 130 174 279 237 65 215 288 21 94 96
2023/2024900 41 77 50 120 141 32 68 126 22 25 29 169
2024/20254.052 133 39 33 256 957 686 433 227 449 167 212 460
2025/20267.151 383 232 384 533 913 393 913 412 740 801 810 637
2026/20272.487 303 616 446 867 255 0 0 0 0 0 0 0
Totale 28.198